1Jason J, Archibald LK, Nwanyanwu OC, et al.Chnical and immune impact of Mycobactefium boris BCG vaccination scarring. Infect Immun, 2002,70: 6188 - 6195.
2Xin KQ, Ooki T, Mizukami H, et al.Oral administration of recombinant adeno- associated virus elicits human immunodeficiency virus-specific immune responses. Hum Gene Ther,2002,13:1571 - 1581.
3Isaka M, Yasuda Y, Kozuka S, et al. Induction of systemic and mucosal antibody resporlses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine, 1999,12:743 - 751.
4Palendira U, Bean AG, Feng CG, et al. Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium boris BCG immunization.Infect Immun,2002,70:1410- 1416.
6Lyadova IV, Vordermeier HM, Eruslanov EB, et al. Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium boris and accelerates production of IFN-gamma in their lungs. Chn Exp Immunol,2001,126:274- 279.
7Chen L, Wang J, Zganiacz A, et al. Single intranasal mucosal Mycobacterium boris BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun, 2004,72: 238 - 246.
8Wang J, Thorson L, Stokes RW. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol, 2004,15 : 6357 - 6365.
9Falero-Diaz G, Challacombe S, Banerjec D, et al.Intranasal vaccination of mice against infection with Mycobacterium tuberculosis. Vaccine, 2000,18 : 3223 - 3229.
10Tree JA, Williams A, Clark S, et al. Intranasal bacille CalmetteGuerin (BCG) vaccine dosage needs balancing between protection and lung pathology. Clin Exp Immunol, 2004, 138: 405 -409.
2Maionel D, Margaritl I, Rinaudol CD, et al. Identification of a universal group B streptococcus vaccine by multiple genome screen [J]. Science, 2005, 309 (7): 148-150.
3Centers for Diseases Control and Prevention. Perinatal group B streptococcal disease after universal screening recommendations-United States, 2003- 2005 [J]. MMWR Morb Mortal Wkly Rep, 2007, 56 (5): 701 705.
4Law MR, Palomaki G, Alfiervic Z, et al. The prevention of neonatal group B strepotoccal disease: a report by a working group of the Medical Screening Society [J]. Med Screen, 2005, 12 (2): 60-68.
5Center for Disease Control and Prevention. Decreasing incidence of perinatal group B streptococcus disease, United States, 1999-2005 [J].JAMA, 2008, 299 (17): 2056-2065.
6Lee BC, Lee TH, Avraham S, et al. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 alpha in breast cancer cell migration through human brain microvascular endothelial cells [J]. Mol Cancer Res, 2004, 2 (6):327-338.
7Leonard EG, Canaday DH, Harding CV, et al. Antigen processing of the heptavalent pneumococcal conjugate vaccine carrier protein CRM197 differs depending on the serotype of the attached polysaccharide [J].Infect Immun, 2003, 71 (7): 4186-4189.
8Gilbert GL. Vaccines for other neonatal infections are group B streptococcal infections vaccine-preventable [J]. Expect Rev Vaccines, 2004, 3 (4): 371-374.
